Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Pol Pharm ; 74(2): 605-610, 2017 Mar.
Article in English | MEDLINE | ID: mdl-29624265

ABSTRACT

Curcuma longa L. (turmeric) of ginger family (Zingiberaceae) belongs to the group of oldest cultivated spice plants in the south-east Asian countries. For many years rhizome of this plant has been used also as a safe and active drug for the treatment of various.chronic diseases, especially of diabetes mellitus (DM). The active substance of turmeric - curcumin (diferuloylmethane), possesses multiple therapeutic properties. In recent years, many detailed research (tests in vito and in vivo) along with clinical trials have revealed its very valuable biological activities related to its anti-inflammatory, antioxidant and cancer preventive properties, which are presented in numerous publications (1-6). At the molecular level it has been stated that curcumin inhibits cell proliferation, metastasis creation and apoptosis. Currently, great attention has been focused on curcumin as a blocker of TNF-s, which are the principal mediators of most inflammation-related disturbances (7). The main cause of blocking the broadly extended pharmacological and clinical investigations of curcumin is its extremely low solubility in water and in organ fluids. This feature consequently limits its systemic bioavailability and makes use of curcumin as a therapeutic remedy (to date) difficult. The primary aim of presently conducted research is to achieve increased solubilization and bioavailability of this promising nontoxic agent.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antioxidants/therapeutic use , Curcuma , Diabetes Complications/drug therapy , Plant Extracts/therapeutic use , Animals , Anti-Inflammatory Agents/adverse effects , Anti-Inflammatory Agents/isolation & purification , Antioxidants/adverse effects , Antioxidants/isolation & purification , Curcuma/adverse effects , Curcuma/chemistry , Diabetes Complications/immunology , Humans , Phytotherapy , Plant Extracts/adverse effects , Plant Extracts/isolation & purification , Plants, Medicinal , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/immunology
2.
J Ovarian Res ; 7: 90, 2014 Sep 27.
Article in English | MEDLINE | ID: mdl-25297939

ABSTRACT

BACKGROUND: The authors used the lipid index (WL) to monitor lipid changes before and after surgery. The surgical operation performed was the simultaneous enucleation of a cystic tumor of the hilum ovarii in its entirety (with diagnosis of a simple cyst or teratoma adultum) in groups of 20 patients. OBJECTIVES: To compare the lipid index WL in the blood serum of patients undergoing surgery treatment at the following times: before and 7 days after surgery, and 6 and 12 months after surgery. MATERIAL AND METHODS: The research material was the blood serum of women aged about 24 years. The authors divided the patients into 3 groups: two groups of 20 women and a control group. The concentrations of the lipid parameters were measured and the lipid index WL was calculated. RESULTS: Statistically significant differences were found between the lipid index of serum from patients with diagnosed ovarian neoplasms and the index of serum from healthy subjects; differences were demonstrated in the postoperative period, particularly 6 and 12 months after surgery. CONCLUSIONS: The lipid index WL proved useful in diagnosing ovarian neoplasm (simple cysts and teratoma adultum) and in monitoring the postoperative period.


Subject(s)
Lipids/blood , Ovarian Neoplasms/blood , Ovarian Neoplasms/pathology , Ovary/pathology , Adolescent , Adult , Case-Control Studies , Female , Humans , Hyperplasia , Neoplasm Staging , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/surgery , Prognosis , Young Adult
3.
Acta Pol Pharm ; 71(4): 687-90, 2014.
Article in English | MEDLINE | ID: mdl-25272896

ABSTRACT

Ibuprofen is a popular over-the-counter, non-steroidal anti-inflammatory medication, frequently used for the relief of fever, headaches, menstrual and other minor pains as well as a major active ingredient in numerous cold preparations. We analyzed sales volume and data obtained from the monitoring of spontaneous reports on the adverse effects of IBUM soft capsules, IBUM Forte soft capsules, and IBUM oral suspension 100 mg/5 mL collected by the manufacturer (PPF HASCO-LEK S.A. Wroclaw, Poland) and National Monitoring Center in Warszawa in the period between October 2002 and June 2012. A total of 19,644,797 units of IBUM soft capsules 200 mg, 5,678,164 units of IBUM Forte soft capsules 400 mg and 4,333,325 units of IBUM oral suspension 100 mg/5 mL (29,656,286 units altogether) produced by PPF HASCO-LEK S.A. Wrodcaw, P'oland were marketed during the period analyzed. There were 5 spontaneous reports regarding these medications registered in Poland in the period analyzed. Forms of oral ibuprofen are very safe medication rarely causing adverse effects; nevertheless, the existing spontaneous monitoring system of adverse effects in Poland is not sensitive enough to detect all adverse effects and needs improvement.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Ibuprofen/adverse effects , Administration, Oral , Adult , Child , Child, Preschool , Female , Humans , Male , Poland
4.
Acta Pol Pharm ; 71(1): 145-51, 2014.
Article in English | MEDLINE | ID: mdl-24779203

ABSTRACT

The possibility of applying liposomes as a topical drug delivery system is still a matter of intensive research. The purpose of this study was to determine the suitability of liposomes as carriers of naproxen and to prove their impact on the effectiveness of transdermal permeation of an active substance. The study was conducted with the use of Franz Diffusion Cell System by comparing the efficacy of a preparation containing 20% of phosphatidylcholine (PC) and 10% of naproxen with reference preparations, i.e., a formulation containing 10% of naproxen without PC and the commercial product Naproxen 10%, gel. The largest transdermal penetration flux of naproxen and the highest efficacy of naproxen permeation were obtained for the formulation containing 10% of naproxen and 20% of PC. The study of the influence of liposomes size and topology on the transdermal diffusion of naproxen (large unilamellar vesicle, LUV, multilamellar vesicle, MLV) showed that there was no statistically significant difference in the flux or total amounts of transdermally diffused naproxen between compared formulations. In conclusion, liposomes present in a formulation double the efficacy of the transdermal permeation of naproxen in vitro compared to reference preparations containing no carriers. Better permeation effect of a formulation was not related to the liposome type (LUV or MLV).


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Naproxen/administration & dosage , Skin Absorption , Administration, Cutaneous , Humans , Liposomes , Naproxen/pharmacokinetics , Skin/metabolism
5.
AAPS PharmSciTech ; 15(1): 111-20, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24166667

ABSTRACT

The identification of new contaminants is critical in the development of new medicinal products. Many impurities, such as pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, decanedioic acid, undecanedioic acid, dodecanedioic acid, tridecanedioic acid, and tetradecanedioic acid, have been identified in samples of azelaic acid. The aim of this study was to identify impurities observed during the stability tests of a new liposomal dosage form of azelaic acid that is composed of phosphatidylcholine and a mixture of ethyl alcohol and water, using high-performance liquid chromatography with evaporative light-scattering detector (HPLC-ELSD), gas chromatography-flame ionisation detection (GC-FID), and gas chromatography-mass spectrometry (GC-MS) methods. During the research and development of a new liposomal formulation of azelaic acid, we developed a method for determining the contamination of azelaic acid using HPLC-ELSD. During our analytical tests, we identified a previously unknown impurity of a liposomal preparation of azelaic acid that appeared in the liposomal formulation of azelaic acid during preliminary stability studies. The procedure led to the conclusion that the impurity was caused by the reaction of azelaic acid with one of the excipients that was applied in the product. The impurity was finally identified as an ethyl monoester of azelaic acid. The identification procedure of this compound was carried out in a series of experiments comparing the chromatograms that were obtained via the following chromatographic methods: HPLC-ELSD, GC-FID, and GC-MS. The final identification of the compound was carried out by GC with MS.


Subject(s)
Dicarboxylic Acids/chemistry , Drug Contamination , Liposomes/chemistry , Chemistry, Pharmaceutical/methods , Chromatography, High Pressure Liquid/methods , Dosage Forms , Ethanol/chemistry , Gas Chromatography-Mass Spectrometry/methods , Phosphatidylcholines/chemistry , Water/chemistry
6.
ScientificWorldJournal ; 2013: 564962, 2013.
Article in English | MEDLINE | ID: mdl-24228008

ABSTRACT

In the course of research and development of a new pharmaceutical formulation of azelaic acid in the liposomal form, we developed a rapid and accurate method for the detection of impurities using high-performance liquid chromatography. A chromatographic column from Merck (Purospher Star RP C18, 250-4 mm (5 µm) was used in the assay, and the mobile phase gradient consisted of three phases: A--methanol : water (5 : 95) + 1.5% (v/v) acetic acid; B--water : methanol (5 : 95) + 1.5% (v/v) acetic acid; and C--chloroform. Detection of the impurities and the active substance was performed by an evaporative light-scattering detector. The method was validated for selectivity, system precision, method precision, limit of detection, and response rates. The proposed method can be used to detect impurities in the liposomal formulation of azelaic acid. The method enables separation of azelaic acid from the identified and unidentified impurities and from the excipients used in the drug form.


Subject(s)
Chromatography, High Pressure Liquid/methods , Dicarboxylic Acids/analysis , Drug Contamination , Liposomes/chemistry , Chemistry, Pharmaceutical , Dermatologic Agents/analysis , Dicarboxylic Acids/chemistry , Light , Limit of Detection , Scattering, Radiation
7.
Respir Physiol Neurobiol ; 187(1): 82-7, 2013 Jun 01.
Article in English | MEDLINE | ID: mdl-23473923

ABSTRACT

Elite athletes have a higher prevalence of exercise-induced bronchoconstriction than the general population. The pathogenesis of exercise-induced bronchoconstriction is not fully elucidated. Increasing evidence suggests that airway inflammation plays a major role in the immunopathogenesis of exercise-induced bronchoconstriction. The aim of our review is to discuss existing evidence and to present a new, modified inflammatory hypothesis of exercise-induced bronchoconstriction. Exercise alters the number and function of circulating immune cells. Episodes of upper respiratory symptoms in elite athletes do not follow the usual seasonal patterns. Moreover, they have an unusual short-term duration, which suggests a non-infectious etiology. If the pro-inflammatory response to exercise has the potential to induce symptoms that mimic respiratory tract infection, it definitely up-regulates pro-inflammatory cytokine expression in the airways. We can conclude that exercise up-regulates airway cytokine expression in a way that favors inflammation and allergic reactions in bronchi and lowers the threshold for bronchoconstriction to different stimuli like cool, dry air, allergens, and pollutants.


Subject(s)
Asthma, Exercise-Induced/immunology , Athletes , Exercise/physiology , Inflammation/immunology , Inflammation/physiopathology , Asthma, Exercise-Induced/physiopathology , Humans
8.
Biophys Chem ; 129(2-3): 120-5, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17566633

ABSTRACT

There is a constant need for simple, economical and time-efficient methods which allow evaluating a compound's ability to penetrate the biological membrane, one of the key parameters needed to characterize biologically active compounds. In the paper we propose a new method of permeability determination. Instead of detecting the compound's concentration directly, we employ an approach in which the membrane interface is labeled with a fluorescein lipid probe; the probe is sensitive to the presence of charged compounds. The fluorescence intensity changes of the dye permanently attached to both sides of a model lipid bilayer are measured. Specifically, the time course of the fluorescence intensity changes following a rapid induction of a non-equilibrium state of the sample allows the evaluation of the membrane permeability for the compound. The method was validated by the determination of the phenyltin compound's transport through the model phosphatidylcholine unilamellar liposome bilayer.


Subject(s)
Lipid Bilayers/metabolism , Spectrometry, Fluorescence/methods , Biological Transport , Fluorescence , Lipid Bilayers/chemistry , Organotin Compounds/analysis , Organotin Compounds/metabolism , Permeability
SELECTION OF CITATIONS
SEARCH DETAIL
...